Immune Checkpoint Equipment & Supplies
51 equipment items found
Manufactured by:Elpiscience based inShanghai, CHINA
LAG3 is an immune checkpoint receptor known to suppress T cell activation. We designed ES005 to block LAG3 ligands, including MHC class II and FGL1. Through unique epitope binding, ES005 is able to recognize human LAG3 with high affinity. In preclinical studies, ES005 inhibited tumor growth both as a monotherapy and in combination with a PD-1 ...
Manufactured by:Promega Corporation based inMadison, WISCONSIN (USA)
The antibodies used to stimulate T cell activation via interaction with co-stimulatory receptors on the effector cells can be cross-linked via binding to FcγRIIb receptors on CHO-K1 cells. Based on the properties of the antibody tested, the Co-Stimulatory Immune Checkpoint (i.e., OX40, CD40, GITR and 4-1BB) bioassays can be conducted in a single ...
Manufactured by:Promega Corporation based inMadison, WISCONSIN (USA)
4-1BB (CD137/TNFRSF9), a member of the tumor necrosis factor receptor superfamily, is an inducible co-stimulatory receptor expressed on T cells, natural killer (NK) cells and innate immune cell populations. When present on the cell surface, 4-1BB interacts with 4-1BB ligand (4-1BBL) and induces subsequent cell proliferation and production of interferon gamma (IFNγ) and interleukin-2 (IL-2), ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
Cancer immunotherapy has therapeutic efficacy in a limited number of patients. Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress anti-tumor activity. However, only a limited fraction of patients benefits from the therapeutic response obtained with these biologic drugs. ...
Manufactured by:CytomX Therapeutics, Inc. based inSouth San Francisco, CALIFORNIA (USA)
Bristol Myers Squibb is enrolling patients in the dose escalation phase of a Phase 1/2a clinical trial (NCT03994601) of a second anti-CTLA-4 Probody, BMS-986288, based on a modified version of Yervoy® (ipilimumab), to evaluate a CTLA-4-directed Probody therapeutic alone or in combination with Opdivo® (nivolumab) in patients with selected advanced solid cancers. CTLA-4, a clinically ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
B7-H3 expression has been detected in a wide range of solid tumors including lung, breast, colorectal, liver and skin cancers. It has also been observed on tumor vasculature and stroma, has been hypothesized to be an immune checkpoint and to be expressed on cancer stem cells, making it promising target for the treatment of metastatic disease. The broad B7-H3 ...
Manufactured by:Elpiscience based inShanghai, CHINA
It has a unique mechanism of action as 4-1BB activation is dependent on PD-L1 binding. 4-1BB is a T cell co-stimulatory receptor and is a compelling immune checkpoint target. 4-1BB targeting antibodies being developed by multinational companies have exhibited dose-dependent liver toxicity in clinical trials, thereby limiting dose-escalation and ultimately their ...
by:Genmab A/S based inCopenhagen V, DENMARK
DuoBody-CD3xB7H4 (GEN1047) is a proprietary bispecific antibody created using Genmab’s DuoBody® technology. B7H4 is an immune checkpoint protein expressed on malignant cells in various solid cancers including breast, ovarian and lung cancer. In preclinical studies, DuoBody-CD3xB7H4 was shown to induce T-cell mediated cytotoxicity of B7H4-positive tumor ...
Manufactured by:AC BioScience SA based inEpalinges, SWITZERLAND
Our patented Beta-carboline derivative (ACB1801) is an actin dynamic modulator which induces cellular F-actin network remodeling (tumor reversal); this in turn translates into immuno-competency that allows the immune system to recognize tumor cells and thereby enhances the efficacy of checkpoint-inhibitor immune therapy. Immune ...
Manufactured by:InnoPep Inc. based inSan Diego, CALIFORNIA (USA)
Programed cell death protein 1 (PD-1) is a cell surface receptor. PD-1 and its ligand PD-L1 are crucial immune checkpoints to downregulate T cell activation, tolerance and immunopathology. Several types of cancer cells overexpress PD-L1 in order to escape from the PD-1/PD-L1 immunosurveillance mechanism. Human PD-L1 inhibitor II is a peptide-based molecule. ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
B7H3 belongs to the B7 family of immune checkpoint inhibitors and is expressed on a wide range of solid and hematologic malignancies. B7H3 is an important mediator of tumor angiogenesis and metastasis, and higher expression is associated with a poor prognosis for patients. ...
Manufactured by:Ocean Biomedical based inProvidence, RHODE ISLAND (USA)
Our lead program, OCX-253 was chosen because it stimulates the B-Raf protooncogene while inhibiting apoptosis, NK cell accumulation and activation, LIM kinase 2, p-cofilin, the tumor suppressor PTEN, and p53. In addition, OCX-253 is a master stimulator of immune checkpoint inhibitor pathways. and plays a critical role in the pathogenesis of primary and metastatic ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Vorbipiprant (CR6086) is an EP4 receptor antagonist, serving as a targeted immunomodulator. Thus, Vorbipiprant is also a potential immune checkpoint inhibitor, to turn cold tumors into hot tumors. Vorbipiprant also antagonizes PGE2-stimulated cAMP production (IC50=22 nM). Vorbipiprant exhibit striking DMARD effects in rodents, and anti-inflammatory activity to ...
Manufactured by:Synaffix BV based inOss, NETHERLANDS
Enabling immune cell engagers & other protein ...
by:Fusix Biotech based inMünchen, GERMANY
The FUSIX Technology relies on a fusion-based oncolytic virus platform. Below you can see FUB101 in action. In this timelapse video FUB101 is killing a monolayer of cancer cells (HCC) within 48 hours through a fusogenic mechanism of action. The FUSIX technology is based on a hybrid virus construct combining all the advantages of both parental platforms while minimizing risks factors. This ...
Manufactured by:Eutilex Co.,Ltd. based inSeoul, SOUTH KOREA
Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of ...
Manufactured by:OSE Immunotherapeutics based inNantes, FRANCE
A novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets being developed by the Company to fight primary and secondary resistance mechanisms developed by cancers to evade checkpoint inhibitor ...
Manufactured by:MedGenome Inc. based inCounty of New Castle, DELAWARE (USA)
OncoPeptTUME — A novel in-silico approach to model the tumor microenvironment and predict treatment efficacy and long-term survival benefits for immunotherapy applications. Cancer immunotherapy is now established as a major therapeutic modality. Cancer immunotherapy drugs elicit their anti-tumor immune response in a subset of the treated patients by activating CD8 T-cells and provide ...